[{"id":"1c48e572-289e-4bd6-8e9e-55f35357c771","acronym":"SCALOP-2","url":"https://clinicaltrials.gov/study/NCT02024009","created_at":"2025-02-25T14:34:28.767Z","updated_at":"2025-02-25T14:34:28.767Z","phase":"Phase 1/2","brief_title":"Systemic Therapy and Chemoradiation in Advanced Localised Pancreatic Cancer - 2","source_id_and_acronym":"NCT02024009 - SCALOP-2","lead_sponsor":"University of Oxford","biomarkers":" KRAS","pipe":"","alterations":" ","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gemcitabine • capecitabine • albumin-bound paclitaxel • Viracept (nelfinavir)"],"overall_status":"Completed","enrollment":" Enrollment 159","initiation":"Initiation: 03/01/2016","start_date":" 03/01/2016","primary_txt":" Primary completion: 06/23/2021","primary_completion_date":" 06/23/2021","study_txt":" Completion: 06/23/2021","study_completion_date":" 06/23/2021","last_update_posted":"2024-07-25"},{"id":"00b653d7-12d2-4c0a-ad1f-a20655e5ffda","acronym":"","url":"https://clinicaltrials.gov/study/NCT01165645","created_at":"2021-01-18T04:38:52.857Z","updated_at":"2024-07-02T16:35:59.786Z","phase":"","brief_title":"Lopinavir and Ritonavir in Improving Immune Response to Vaccines in Patients With Complete Remission Following A Bone Marrow Transplant for Hodgkin Lymphoma","source_id_and_acronym":"NCT01165645","lead_sponsor":"Mayo Clinic","biomarkers":" CD8 • IL6 • TNFA • CXCL8 • CD4 • IL2 • IL10 • IL4 • IL7","pipe":"","alterations":" ","tags":["CD8 • IL6 • TNFA • CXCL8 • CD4 • IL2 • IL10 • IL4 • IL7"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 11/01/2010","start_date":" 11/01/2010","primary_txt":" Primary completion: 05/01/2011","primary_completion_date":" 05/01/2011","study_txt":" Completion: 12/14/2011","study_completion_date":" 12/14/2011","last_update_posted":"2022-12-01"},{"id":"296c96e7-b22e-4040-a519-2e7ecf12e1f7","acronym":"","url":"https://clinicaltrials.gov/study/NCT03147378","created_at":"2021-10-19T13:55:36.804Z","updated_at":"2024-07-02T16:36:22.779Z","phase":"Phase 1","brief_title":"Food Effect Study of ModraDoc006 in Combination With Ritonavir","source_id_and_acronym":"NCT03147378","lead_sponsor":"Modra Pharmaceuticals","biomarkers":" ABCB1 • ABCC2","pipe":"","alterations":" ","tags":["ABCB1 • ABCC2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e docetaxel oral/ritonavir (ModraDoc006/r)"],"overall_status":"Completed","enrollment":" Enrollment 18","initiation":"Initiation: 05/10/2017","start_date":" 05/10/2017","primary_txt":" Primary completion: 04/04/2018","primary_completion_date":" 04/04/2018","study_txt":" Completion: 04/04/2018","study_completion_date":" 04/04/2018","last_update_posted":"2021-10-19"},{"id":"dd1a6cf8-4d0d-4d05-81ed-0f9c70167f2c","acronym":"","url":"https://clinicaltrials.gov/study/NCT03890744","created_at":"2021-01-18T19:09:46.227Z","updated_at":"2024-07-02T16:36:22.803Z","phase":"Phase 2a","brief_title":"ModraDoc006/r in Patients With Breast Cancer","source_id_and_acronym":"NCT03890744","lead_sponsor":"Modra Pharmaceuticals","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e docetaxel oral/ritonavir (ModraDoc006/r)"],"overall_status":"Completed","enrollment":" Enrollment 12","initiation":"Initiation: 01/30/2019","start_date":" 01/30/2019","primary_txt":" Primary completion: 02/13/2020","primary_completion_date":" 02/13/2020","study_txt":" Completion: 11/09/2020","study_completion_date":" 11/09/2020","last_update_posted":"2021-10-19"},{"id":"e0dcfabe-9736-4024-9d54-13cb06f97e30","acronym":"SAKK 65/08","url":"https://clinicaltrials.gov/study/NCT01164709","created_at":"2021-01-18T04:38:37.477Z","updated_at":"2024-07-02T16:36:59.561Z","phase":"Phase 1","brief_title":"Nelfinavir Mesylate and Bortezomib in Treating Patients With Relapsed or Progressive Advanced Hematologic Cancer","source_id_and_acronym":"NCT01164709 - SAKK 65/08","lead_sponsor":"Swiss Group for Clinical Cancer Research","biomarkers":" ALK • TNFRSF8","pipe":" | ","alterations":" ALK positive • TNFRSF8 positive • ALK negative","tags":["ALK • TNFRSF8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK positive • TNFRSF8 positive • ALK negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e bortezomib • Viracept (nelfinavir)"],"overall_status":"Completed","enrollment":" Enrollment 18","initiation":"Initiation: 07/01/2010","start_date":" 07/01/2010","primary_txt":" Primary completion: 07/01/2012","primary_completion_date":" 07/01/2012","study_txt":" Completion: 11/01/2013","study_completion_date":" 11/01/2013","last_update_posted":"2019-05-15"},{"id":"230a4eb0-75f1-40c7-9045-a482f4f529d7","acronym":"","url":"https://clinicaltrials.gov/study/NCT01609933","created_at":"2021-01-18T06:53:33.286Z","updated_at":"2024-07-02T16:37:09.955Z","phase":"Phase 2","brief_title":"A Study to Evaluate the Safety and Effect of Treatment With Experimental Antiviral Drugs in Combination With Peginterferon Alpha-2a and Ribavirin in People With Hepatitis C Virus Who Did Not Respond to Treatment in a Previous AbbVie/Abbott Combination Study","source_id_and_acronym":"NCT01609933","lead_sponsor":"AbbVie (prior sponsor, Abbott)","biomarkers":" IFNA1","pipe":"","alterations":" ","tags":["IFNA1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ritonavir"],"overall_status":"Completed","enrollment":" Enrollment 32","initiation":"Initiation: 12/18/2012","start_date":" 12/18/2012","primary_txt":" Primary completion: 05/03/2017","primary_completion_date":" 05/03/2017","study_txt":" Completion: 05/03/2017","study_completion_date":" 05/03/2017","last_update_posted":"2018-06-19"},{"id":"10d15577-1976-4637-a837-428e95cca323","acronym":"","url":"https://clinicaltrials.gov/study/NCT01009437","created_at":"2021-01-18T03:56:59.867Z","updated_at":"2024-07-02T16:37:15.831Z","phase":"Phase 1/2","brief_title":"Ritonavir and Its Effects on Biomarkers in Women Undergoing Surgery for Newly Diagnosed Breast Cancer","source_id_and_acronym":"NCT01009437","lead_sponsor":"Masonic Cancer Center, University of Minnesota","biomarkers":" HER-2 • ER • PGR • IL6 • TNFA • STAT3 • HSPA5 • ATF4 • HSP90AA1","pipe":" | ","alterations":" ER positive • HER-2 negative","tags":["HER-2 • ER • PGR • IL6 • TNFA • STAT3 • HSPA5 • ATF4 • HSP90AA1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ritonavir"],"overall_status":"Completed","enrollment":" Enrollment 28","initiation":"Initiation: 05/26/2010","start_date":" 05/26/2010","primary_txt":" Primary completion: 07/01/2014","primary_completion_date":" 07/01/2014","study_txt":" Completion: 07/01/2014","study_completion_date":" 07/01/2014","last_update_posted":"2017-12-05"},{"id":"2214b856-b2d7-49fd-b17c-ae1344695b73","acronym":"","url":"https://clinicaltrials.gov/study/NCT00436735","created_at":"2021-01-18T01:32:30.542Z","updated_at":"2024-07-02T16:37:17.257Z","phase":"Phase 1","brief_title":"Nelfinavir in Treating Patients With Metastatic, Refractory, or Recurrent Solid Tumors","source_id_and_acronym":"NCT00436735","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CYP3A4","pipe":"","alterations":" ","tags":["CYP3A4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Viracept (nelfinavir) • midazolam hydrochloride"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 45","initiation":"Initiation: 09/01/2006","start_date":" 09/01/2006","primary_txt":"","primary_completion_date":"","study_txt":"","study_completion_date":"","last_update_posted":"2017-10-06"}]